MPH Medicure Inc

Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(OTCQB:MCUJF), a
specialty pharmaceutical company, reports that, in view of the recent market
activity in the Company's stock, the Investment Industry Regulatory Organization
of Canada ("IIROC") has contacted the Company in accordance with its usual
practice. 


Although the Company ordinarily does not comment on market activity or market
speculation, the Company is aware of the increased market activity in its common
stock subsequent to our most recent press releases, including the announcement
of March 26, 2014 relating to the financial results from the third quarter
fiscal 2014 and the announcement of April 14, 2014 relating to the Company's
advisory services agreement with Knight Therapeutics Inc.


Over the past several years the Company has been exploring opportunities to grow
its business through acquisition. The Company is currently pursuing one specific
opportunity, under which the Company would be a party to an acquisition. There
is no assurance that this potential transaction, or any other transaction, is
going to be completed.


The transaction contemplated is subject to, among other things, the negotiation
and execution of a definitive binding agreements and other documentation,
approval of the board of directors of the Company and that of the other parties
to the transaction, and the completion of remaining due diligence activities.
There can be no assurance that these conditions precedent, or any other
conditions precedent, will be satisfied. 


About Medicure Inc.

Medicure is a specialty pharmaceutical company focused on the development and
commercialization of novel small molecule therapeutics. The primary focus of the
Company and its subsidiaries is the marketing and distribution of AGGRASTAT
(tirofiban HCl) for non-ST elevation acute coronary syndrome in the United
States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma,
Inc. For more information on Medicure please visit www.medicure.com. 


To be added to Medicure's e-mail list, please visit:
http://medicure.com/newsreleases.html. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release. Forward Looking Information Statements
contained in this press release that are not statements of historical fact,
including, without limitation, statements containing the words "believes",
"may", "plans", "will", "estimates", "continues", "anticipates", "intends",
"expects" and similar expressions, may constitute "forward-looking information"
within the meaning of applicable Canadian and U.S. federal securities laws (such
forward-looking information and forward-looking statements are hereinafter
collectively referred to as "forward-looking statements"). Forward-looking
statements, including the potential for any growth through acquisition, are
based on the current assumptions, estimates, analysis and opinions of management
of the Company made in light of its experience and its perception of trends,
current conditions and expected developments, as well as other factors which the
Company believes to be relevant and reasonable in the circumstances. Inherent in
forward-looking statements are known and unknown risks, uncertainties and other
factors beyond the Company's ability to predict or control that may cause the
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements, and as such, readers are cautioned not to place
undue reliance on forward-looking statements. 

Such risk factors include, among others, the Company's future product revenues,
stage of development, additional capital requirements, risks associated with the
completion and timing of clinical trials and obtaining regulatory approval to
market the Company's products, the ability to protect its intellectual property,
dependence upon collaborative partners, changes in government regulation or
regulatory approval processes, and rapid technological change in the industry.
Such statements are based on a number of assumptions which may prove to be
incorrect, including, but not limited to, assumptions about: general business
and economic conditions; the impact of changes in Canadian-US dollar and other
foreign exchange rates on the Company's revenues, costs and results; the timing
of the receipt of regulatory and governmental approvals for the Company's
research and development projects; the availability of financing for the
Company's commercial operations and/or research and development projects, or the
availability of financing on reasonable terms; results of current and future
clinical trials; the uncertainties associated with the acceptance and demand for
new products and market competition. The foregoing list of important factors and
assumptions is not exhaustive. The Company undertakes no obligation to update
publicly or otherwise revise any forward-looking statements or the foregoing
list of factors, other than as may be required by applicable legislation.
Additional discussion regarding the risks and uncertainties relating to the
Company and its business can be found in the Company's other filings with the
applicable Canadian securities regulatory authorities or the US Securities and
Exchange Commission, and in the "Risk Factors" section of its Form 20F for the
year ended May 31, 2013. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Medicure Inc.
Dawson Reimer
President & COO
888-435-2220
204-488-9823 (FAX)
info@medicure.com
www.medicure.com

Medicure (TSXV:MPH)
Historical Stock Chart
From Mar 2024 to Apr 2024

Medicure (TSXV:MPH)
Historical Stock Chart
From Apr 2023 to Apr 2024